# Braegen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/braegen

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.braegen.com.cn
- Latest round: Series A (Nov 19, 2024)
- Investors on record: 4

## About

Founded in 2015 and based in Shenzhen, China, Braegen specializes in developing drugs for central nervous system disorders. In November 2024, the firm closed a series A+ funding. The company has R&D management teams and technology transformation centers in Shanghai and Shenzhen respectively. Jie Zhang, the company's co-founder and CEO, was formerly executive vice president of MicroPort Medical.

Braegen Pharmaceutical focuses on developing innovative drugs for central nervous system (CNS) diseases. Their flagship product, BrAD-R13, is a first-in-class small molecule TrkB receptor agonist aimed at treating mild to moderate Alzheimer's disease. Additionally, the company is developing a PET imaging agent for early Parkinson's disease diagnosis, targeting markets in North America and Asia.

The company’s revenue is generated by providing small molecule oral drugs and radiopharmaceuticals.

The company plans to utilize the series A+ funding to support the ongoing development of BrAD-R13 and the PET imaging agent.

## Funding rounds

- Series A, Nov 19, 2024 — Cowin Capital, TusStar, Casstar Capital
- Series A, Dec 27, 2023 — Zhongke Angel Fund

## Investors

- Zhongke Angel Fund (https://capitalatlas.ai/funds/zhongke-angel-fund) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- TusStar (https://capitalatlas.ai/funds/tusstar) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A